Kidney injury and disease in patients with haematological malignancies Review
| Authors: | Bridoux, F.; Cockwell, P.; Glezerman, I.; Gutgarts, V.; Hogan, J. J.; Jhaveri, K. D.; Joly, F.; Nasr, S. H.; Sawinski, D.; Leung, N. |
| Review Title: | Kidney injury and disease in patients with haematological malignancies |
| Abstract: | Acute kidney injury (AKI) is common in patients with cancer, especially in those with haematological malignancies. Kidney injury might be a direct consequence of the underlying haematological condition. For example, in the case of lymphoma infiltration or extramedullary haematopoiesis, it might be caused by a tumour product; in the case of cast nephropathy it might be due to the presence of monoclonal immunoglobulin; or it might result from tumour complications, such as hypercalcaemia. Kidney injury might also be caused by cancer treatment, as many chemotherapeutic agents are nephrotoxic. High-intensity treatments, such as high-dose chemotherapy followed by haematopoietic stem cell transplantation, not only increase the risk of infection but can also cause AKI through various mechanisms, including viral nephropathies, engraftment syndrome and sinusoidal obstruction syndrome. Some conditions, such as thrombotic microangiopathy, might also result directly from the haematological condition or the treatment. Novel immunotherapies, such as immune checkpoint inhibitors and chimeric antigen receptor T cell therapy, can also be nephrotoxic. As new therapies for haematological malignancies with increased anti-tumour efficacy and reduced toxicity are developed, the number of patients receiving these treatments will increase. Clinicians must gain a good understanding of the different mechanisms of kidney injury associated with cancer to better care for these patients. © 2021, Springer Nature Limited. |
| Keywords: | busulfan; fludarabine; review; pathophysiology; bortezomib; multiple myeloma; cell infiltration; cyclophosphamide; dexamethasone; melphalan; hypercalcemia; thiotepa; tumor lysis syndrome; acute kidney failure; hematologic malignancy; nonhodgkin lymphoma; kidney tumor; kidney injury; cancer cell; chronic lymphatic leukemia; monoclonal immunoglobulinemia; thrombotic thrombocytopenic purpura; carfilzomib; extramedullary hematopoiesis; fanconi renotubular syndrome; human; priority journal; ixazomib; daratumumab; lymphocytic lymphoma |
| Journal Title: | Nature Reviews Nephrology |
| Volume: | 17 |
| Issue: | 6 |
| ISSN: | 1759-5061 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2021-06-01 |
| Start Page: | 386 |
| End Page: | 401 |
| Language: | English |
| DOI: | 10.1038/s41581-021-00405-7 |
| PUBMED: | 33785910 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 July 2021 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work